Brain Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Brain Cancer – Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Brain Cancer
- The report reviews pipeline therapeutics for Brain Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Brain Cancer therapeutics and enlists all their major and minor projects
- The report assesses Brain Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Brain Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Brain Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Acrivon Therapeutics IncActinium Pharmaceuticals Inc
AimedBio Inc
AntiRadical Therapeutics LLC
Arjuna Therapeutics
Aurigene Oncology Ltd
Bayer AG
Beijing zhikangbo Medical Oncology Research Co Ltd
Bellicum Pharmaceuticals Inc
Biodexa Pharmaceuticals PLC
Biogenera SpA
Boehringer Ingelheim International GmbH
BPGbio Inc
Bristol-Myers Squibb Co
Calviri Inc
Cancer Research UK
Cardiff Oncology Inc
Cellid Co Ltd
Celprogen Inc
Centessa Pharmaceuticals Plc
Chang Gung Memorial Foundation
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chimerix Inc
Chrysalis BioTherapeutics Inc
Cincinnati Children's Hospital Medical Center
Cotinga Pharmaceuticals Inc
Curasight
Curtana Pharmaceuticals Inc
Dalriada Therapeutics Inc
Disulfican Ltd
Dracen Pharmaceuticals Inc
Edison Oncology Holding Corp
Eisai Co Ltd
Elucida Oncology Inc
F. Hoffmann-La Roche Ltd
Gan & Lee Pharmaceuticals Co Ltd
Genentech USA Inc
General Hospital of the People's Liberation Army
Gennao Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
HB Therapeutics Inc
Hinova Pharmaceuticals Co Ltd
Hudson Institute of Medical Research
Immunomic Therapeutics Inc
ImmunSYS Inc
IMPACT Therapeutics Inc
Incanthera Plc
InnoBioPharma LLC
Institute of Biotechnology and Pharmaceutical Research
Istari Oncology Inc
Kintor Pharmaceutical Ltd
Komipharm International Co Ltd
Laevoroc Oncology AG
LIfT BioSciences Ltd
Lumos Pharma Inc
MacroGenics Inc
Mana Therapeutics Inc
McMaster University
MD2 Biosciences Inc
Medific Inc
MimiVax LLC
Moleculin Biotech Inc
Mustang Bio Inc
N1 Life Inc
Nanjing KAEDI Biotech Inc
Nascent Biotech Inc
Natsar Pharmaceuticals Inc
Neonc Technologies Inc
Neurxstem Inc
Nino Jesus University Children's Hospital
Novartis AG
Noviga Research AB
Nurix Therapeutics Inc
Nuvectis Pharma Inc
OBI Pharma Inc
Ohio State University
Oncoheroes Biosciences Inc
OncoLife Therapeutics Pty Ltd
Oncorus Inc
Oncurious NV
Orphelia Pharma SAS
Orpheus Therapeutics Inc
Patrys Ltd
PENAO Pty Ltd
Pfizer Inc
PharmaEngine Inc
PNB Vesper Life Science Pvt Ltd
Progenics Pharmaceuticals Inc
ProLynx LLC
Quadriga BioSciences Inc
RefleXion Medical Inc
Res Nova Bio Inc
Revolution Medicines Inc
Sapience Therapeutics Inc
Seagen Inc
Segue Therapeutics LLC
Sequoia Vaccines Inc
Shionogi & Co Ltd
Splash Pharmaceuticals Inc
Stanford University
Stanford University School of Medicine
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Oncology
Inc
Sumitomo Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Suntec Medical (Taiwan) Inc
Tasrif Pharmaceutical Inc
The Scripps Research Institute
Travecta Therapeutics Pte Ltd
Treovir LLC
University of Connecticut
University of Florida
University of North Carolina
University of Rochester
University of Utah
Urmia University of Medical Sciences
Vacino Biotech Co Ltd
Valo Health LLC
VBI Vaccines Inc
Viomedix LLC
Vyriad Inc
Vyro Bio Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd
Winship Cancer Institute of Emory University
Wuhan Binhui Biopharmaceutical Co Ltd
Yuhan Corp
Zelira Therapeutics Ltd